mFOLFIRINOX-New Standard of Care For Treatment of Stage I-III Pancreatic Cancer

mFOLRIRINOX improves the treatment of surgically treated pancreatic cancer.

mFOLFIRINOX The New Standard of Care For Treatment of Stage I-III Pancreatic Cancer

by C.H. Weaver M.D. updated 9/1/2018

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings suggest that more aggressive mFOLFIRINOX chemotherapy treatment improves the outcomes of non-metastatic pancreatic cancer compared to single agent Gemzar (gemcitabine) chemotherapy which has been a standard treatment for over a decade.

About Pancreatic Cancer

Pancreatic cancer is one of the deadliest forms of cancer and is projected to become the second leading cause of cancer death by 2020. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage, treatment remains challenging, and new treatment approaches are required.

In the current clinical trial Dr. Conroy and colleagues evaluated the benefit of mFOLFIRINOX chemotherapy in the adjuvant setting in 493 patients with pancreatic who were enrolled in the study from 77 clinical treatment centers in France and Canada. All patients with stage I-III non-metastatic pancreatic adenocarcinoma who had all visible tumor surgically removed were treated with the standard chemotherapy drug Gemzar or a more aggressive multi-drug treatment regimen mFOLFIRINOX for 6 months and directly compared.

At a median follow-up of 33.6 months from the treatment individuals treated with mFOLFIRINOX survived without evidence of cancer an average of 21.6 months compared to only 12.8 months for Gemzar treated patients. The median overall survival was also improved; 54.4 months for mFOLFIRINOX versus 35.0 months for Gemzar.

mFOLFIRINOX Chemotherapy is administered every 2 weeks:

  • Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1
  • Irinotecan 150 mg/m2 IV over 90 minutes on Day 1
  • Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1
  • 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.

mFORFIRINOX was associated with more side effects from treatment but the study authors conclude they were manageable. Dr. Conroy suggested mFOLFIRINOX should be considered the new standard of care for the treatment of pancreatic cancer following surgical resection.

Because of the superiority of mFORFIRINOX utilization of the regimen as neoadjuvant therapy prior to surgery is also appealing. Neoadjuvant therapy can increase the number of patients who are ultimately able to have their cancer removed and early treatment might have the additional benefit of eradicating some cancer cells that had already spread away from the primary cancer.

References:

1.

2. American Society of Clinical Oncology (ASCO) 2018 Annual Meeting. Presented June 4, 2018. Abstract LBA4001

Comments